Company / CIK 0001693415
Translate Bio, Inc.
- Ticker
- TBIO
- Insiders on file
- 1
- Federal contracts on record
- none matched
- Lobbying filings on record
- none matched
- SEC filings
- EDGAR ↗
- Latest trade on record
- September 14, 2021
Translate Bio, Inc. (TBIO) has 1 insider on file who disclosed 0 transactions in the last 12 months (0 open-market buys, 0 sales, about $0 at reported prices). No federal contract award that started in the last 180 days was found for a recipient with exactly this name; no lobbying filing names it as client this year.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Sanofi | Insider | 2 | 2 | 0 | August 12, 2026 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi | TBIO | Buy P | September 14, 2021 | September 14, 2021 | 0d | 20,515,985 | $38 | $779.6M | Form 4 ↗ | ||
| Sanofi | TBIO | Buy P | September 14, 2021 | September 14, 2021 | 0d | 51,467,612 | $38 | $1.96B | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "Translate Bio, Inc.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
No LDA filing posted since October 2025 names "Translate Bio, Inc." as the client. Filings under a subsidiary or trade-association name are not matched — search lobbying.
Related companies
Companies whose stock was traded by the same people who traded TBIO, by number of filers in common. It shows overlap in public filings and nothing else.
- REGENERON PHARMACEUTICALS, INC. REGN 1 filer in common
- Attovia Therapeutics, Inc. ATTO 1 filer in common
- Latigo Biotherapeutics, Inc. LTGO 1 filer in common
- Fulcrum Therapeutics, Inc. FULC 1 filer in common
- Icosavax, Inc. ICVX 1 filer in common
- Inozyme Pharma, Inc. INZY 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 2 | September 14, 2021 | September 14, 2021 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.